uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy.
Manuscript (Other academic)
URN: urn:nbn:se:uu:diva-94168OAI: oai:DiVA.org:uu-94168DiVA: diva2:167924
Available from: 2006-03-31 Created: 2006-03-31 Last updated: 2011-03-01
In thesis
1. Using Pharmacokinetic and Pharmacodynamic Principles to Evaluate Individualisation of Antibiotic Dosing – Emphasis on Cefuroxime
Open this publication in new window or tab >>Using Pharmacokinetic and Pharmacodynamic Principles to Evaluate Individualisation of Antibiotic Dosing – Emphasis on Cefuroxime
2006 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Cefuroxime is a renally eliminated antibiotic used against a variety of different bacterial infections. The pharmacokinetics (PK) for cefuroxime was studied in 97 hospitalized patients using population analysis. To be able to measure cefuroxime in human serum a new sensitive analytical method was developed using mass spectrometry detection. The method was validated and shown to be sensitive and selective. Cystatin C was found to be a better covariate for cefuroxime clearance compared to the traditionally used creatinine clearance (CLcr). This relation might be useful when designing dosing strategies for cefuroxime and other renally eliminated drugs.

The time-courses of the biomarkers C-reactive protein (CRP), serum amyloid A (SAA), interleukin-6 (IL-6) and body temperature were studied for the first 72 hours of cefuroxime treatment and was related to the duration of illness previous treatment with cefuroxime and to time to step-down of treatment. When duration of illness was short, CRP and SAA were showed increasing levels. None of the biomarkers could be used to differentiate between early or late step-down of therapy.

By use of known PK and pharmacodynamic (PD) principles, dosing strategies based on CLcr for cefuroxime were estimated using minimization of a risk function. The risk function was constructed with the aim to expose patients to cefuroxime concentration above minimum inhibitory concentration (MIC) for 50 % of the dosing interval and to minimize the amount of drug administered in excess to reach the aim. Based on evaluation using wild type MIC distributions for Escherichia coli and Streptococcus pneumoniae improved dosing strategies were selected.

In vitro experiments were performed exposing Streptococcus pyogenes to constant concentration of benzylpenicillin, cefuroxime, erythromycin, moxifloxacin or vancomycin. A semi-mechanistic PK/PD model characterizing the time-course of the antibacterial effect was developed using all data simultaneously. Internal validation showed the model being predictive and robust.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2006. 57 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 29
Pharmacokinetics/Pharmacotherapy, Cefuroxime, pharmacokinetics, pharmacodynamics, dosing individualisation, NONMEM, Farmakokinetik/Farmakoterapi
National Category
Pharmaceutical Sciences
urn:nbn:se:uu:diva-6639 (URN)91-554-6499-8 (ISBN)
Public defence
2006-04-21, B22, BMC, Uppsala, 09:15
Available from: 2006-03-31 Created: 2006-03-31 Last updated: 2011-06-27Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Karlsson, Mats O
By organisation
Division of Pharmacokinetics and Drug Therapy

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 206 hits
ReferencesLink to record
Permanent link

Direct link